App-Quantinova.ai

Characterization of KRAS, NRAS, and BRAF testing and timing among mCRC patients treated at community cancer centers in the United States.

Kimberly Lowe - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Current risk stratification for colorectal cancer screening using a blood-based RNA test.

Choong-Chin Liew - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Tumor necrosis factor alpha, a neurotoxic proinflammatory cytokine for oxaliplatin-induced peripheral neuropathy.

Zohreh Ghoreishi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

ILS-969

The role of depth of response and single-nucleotide polymorphisms as a prediction of the efficacy for third line chemotherapy in metastatic colorectal cancer.

Ka-rham Kim - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Association of folate and vitamins involved in the one-carbon cycle with polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene and global DNA methylation in patients with colorectal cancer.

Samuel Aguiar Junior - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Growth differentiation factor 15 (GDF-15) as potential serum biomarkers in patients with metastatic colorectal cancer.

Michal Vocka - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Worse prognosis in young female patients with non-metastatic colorectal cancer: A hospital-based analysis of 5,295 patients in China.

Ji Zhu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Association of chemotherapy induced neutropenia at 1-month mark (CIN-1-month) and overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A Cohort study.

Pashtoon Murtaza Kasi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TAS102

Comparison of efficacy and tolerability of weekly adjuvant chemotherapy for colorectal cancer (CRC) using folinic acid with fluorouracil dosed at 425 mg/m2 or 370 mg/m2.

Michael B. Jameson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Fluorouracil

Assessing the utility and benefit of granulocyte-colony stimulating factor (G-CSF) in adjuvant therapy for stage III colon cancer.

Vishal Vashistha - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Filgrastim

Outcomes of elderly patients receiving neoadjuvant chemoradiation and adjuvant chemotherapy for locally advanced rectal cancer in a retrospective cohort.

Pablo Reguera Puertas - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Analysis of early distant metastases of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer.

Sara Lonardi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

Oxaliplatin

Effects of derivative vitamin D3 in colorectal cancer.

Teruo Sasatomi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

cholecalciferol

Demographic profile and treatment results of non metastatic young rectal cancer patients from a teritiary cancer care centre in India.

Haresh Kunhiparambath - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Capecitabine

Use of clinical factors to predict imaging appearance of bony metastases in colorectal cancer: A retrospective analysis.

Alpana Mukesh Harisinghani - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Update analysis: Thromboembolism in gastrointestinal tract cancer patients receiving chemotherapy.

Ayane Oba - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Is preoperative chemotherapy related to the survival of patient operated for peritoneal colorectal carcinomatosis and can it induce complete pathological response?

Abdelkader Taibi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Chemotherapy tolerance and oncologic outcomes in colorectal cancer (CRC) patients with and without inflammatory bowel disease (IBD).

Celina Ang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Characteristics of local immunity factors in esophageal cancer with varying degrees of differentiation.

Oleg Ivanovich Kit - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Phase II study with docetaxel (D), cisplatin (C) and continuous capecitabine (X) schedule (DCX) in advanced gastric cancer (AGC): ML21085. Final results.

Carles Pericay - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Solid malignancies

Ciprofloxacin

Filters

41730 Abstracts